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Abstract 
Fusarium species cause rare and severe infections. Their incidence is increasing in 
immunocompromised patients but they are also observed in healthy hosts. Because of 
the rapid dissemination of infection and the frequent resistance of Fusarium species to 
antifungal drugs, histopathologic evidence of hyphae is very helpful to obtain the 
diagnosis rapidly. We report the clinical and pathological features of two patients with 
initial cutaneous lesions. Cutaneous early biopsies showed microvessel involvement with 
hyphae and thrombosis. Fusarium infection was confirmed by skin culture. Hyphae 
within a microvessel thrombus in the skin were highly suggestive of disseminated fungal 
infection. These pathological features enabled to establish an early diagnosis and to start 
efficient antifungal treatment. In early cutaneous biopsies of immunocompromised 
patients, the presence of cutaneous vessel thrombosis can suggest a fungal infection and 
may help to start specific therapy without delay for these life-threatening infections. 
Introduction 
Fusarium species cause a broad spectrum of human diseases, ranging from superficial 
or localized infections such as corneal infections, endophthalmitis or onychomycosis in 
healthy hosts, to severe disseminated infection in immunocompromised patients. 23–30% 
of documented fusariosis cases occur after haematopoietic stem cell transplantation 
(HSCT) [1, 2] and, in this population, Fusarium is the second cause of mold infections  
Case Rep Dermatol 2010;2:76–81 
DOI: 10.1159/000313934 
Published online: May 7, 2010  © 2010 S. Karger AG, Basel 
ISSN 1662–6567 
www.karger.com/cde 
 
 
77
after Aspergillus [3]. These infections are associated with high mortality rates (70–87%) 
and their prognosis remains poor [4]. Disseminated infections often develop from an 
initial skin infection. Fusarium species possess angiotropic and angioinvasive properties 
resulting in thrombosis and tissue necrosis. The diagnosis of Fusarium infection is 
determined by blood and/or tissue biopsy culture. The latter is of great importance 
because blood culture may be negative despite blood dissemination. 
We report two cases of disseminated fusariosis with cutaneous lesions, whose biopsies, 
showing hyphae within a microvessel thrombus, enabled to establish an early diagnosis. 
Cases Reports 
Case 1 (fig. 1a) 
A 16-year-old man with hyperleukocytic undifferentiated acute leukaemia secondary to Fanconi 
anaemia underwent stem cell transplantation with double mismatched unrelated umbilical cord blood 
(UCB). Three months before this procedure he had received two courses of chemotherapy with FLAG 
regimen (fludarabine, aracytine and granulocyte-colony-stimulating factor) which had reduced the 
medullary blasts count. However, he kept a severe pancytopenia until his admission for double UCB 
transplant, realized after a nonmyeloablative conditioning regimen with total body irradiation, 
fludarabine and cyclophosphamide. Graft versus host disease prophylaxis was methylprednisolone 
(1 mg/kg), cyclosporine and mycophenolate mofetil. The patient received a second mismatched 
unrelated UCB transplant 7 weeks after the first transplant. One day before the second transplant, he 
developed violaceous, indurated skin lesions and purpuric blisters on the wrist, with fever and elevated 
C-reactive protein despite broad-spectrum antibiotherapy and caspofungin. Skin biopsy, performed two 
days after the onset of the lesions, showed septate, acute-branching hyphae and macroconidia within a 
microvessel thrombus. Antifungal biotherapy associating voriconazole and liposomal amphotericin B 
was immediately started. Progression of skin lesions on both arms, suggestive of disseminated infection 
despite negative blood culture, required the increase of liposomal amphotericin B. Cerebral and lung 
imagery and coagulation tests were normal. No skin necrosis occurred and the lesions progressively 
resolved to disappear by day 45. The patient later developed candidemia and acute graft versus host 
disease with digestive haemorrhage and died 69 days after the second graft. 
Case 2 (fig. 1b) 
A 50-year-old woman, who had had a renal transplant in 2000, followed by 10 mg prednisone and 
1.5 g mycophenolate mofetil daily, developed painful erythematous papules on the leg, with fever for 
3 days. C-reactive protein was elevated. Physical examination showed erythematous papules centered by 
pustules with a homolateral inguinal adenopathy. Lung scan was normal. Skin biopsy, performed 3 days 
after the onset of the eruption, showed broad, septate hyphae with branching ankles and macroconidia 
within a microvessel thrombus. Blood culture was negative. Antifungal biotherapy, associating 
voriconazole and liposomal amphotericin B, was immediately started. No skin necrosis occurred and 
skin lesions disappeared by day 40. 
Pathological Findings 
Skin biopsies were performed early in the course of the disease (two and three days after the onset of 
eruption), before any treatment. They allowed the epidermis, full dermis and subcutaneous fat analyses. 
The lesions were found in the papillary dermis (fig. 1a) and in the hypodermis (fig. 1b) in the 
microvessel network. In the two cases, microvessel thrombus was associated with septate, 
acute-branching hyphae and macroconidia well shown on special stain. Skin cultures isolated Fusarium 
sp. Fusarium subglutinans, close to Gibberella fujikuroi complex was identified by DNA sequencing in 
case 1 (Centre National de Référence des Mycoses et des Antifongiques, Institut Pasteur, Paris, France). 
Fusarium solani was identified by phenotypic methods in case 2. The cultures yielded colonies that were 
white to creamy in colour with a loccose aerial mycelium. Slide cultures on Sabouraud’s agar revealed 
oval microconidia sometimes grouped in verticilliums produced from elongated lateral phialides. We 
observed a few intercalary, rough-walled chlamydospores [5].   
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Discussion 
Skin biopsy early in the course of two cases of Fusarium infection allowed us to detect 
microvessel thrombosis and hyphae in the papillary dermis and hypodermis. Fusarium 
infection incidence is growing in immunocompromised patients and reported rates vary 
from 0.4 to 2% after allogeneic HSCT [6]. However, these infections can also occur in 
healthy persons, resulting in keratitis or onychomycosis or less frequently in skin 
infection after face trauma, eye surgery, burns or wounds [2]. For immunocompromised 
patients, profound and prolonged neutropenia and high doses of corticosteroids are 
the most important underlying risk factors. Other risk factors include HSCT, HLA-
mismatched compared to HLA-matched transplant and central venous catheter use [1, 4]. 
Persistent neutropenia is also a major predictor of mortality [4]. Our two cases were 
immunocompromised. The onset of the fusariosis infection was characterized by skin 
lesions.  
Skin has been found to be involved in more than 70% of patients with Fusarium 
infection and this incidence increases until 75–90% in disseminated infections [2]. Skin 
infectious entry door concerned 33% of affected patients [1]. The disease can be limited to 
the initial skin lesion, or extend to other skin locations or other organs, predominantly 
blood (70%), lungs (39%) and sinuses (18%) [3]. Even though, in these cases, blood 
culture was negative, detection of Fusarium inside the thrombosis suggested that blood 
was probably involved. Usually, skin lesions are macules or papules with or without 
central necrosis, pustules, or subcutaneous nodules [7]. Bodey et al. have observed 
necrosis of skin papules in more than 60% of disseminated Fusarium infections [2]. 
Haemorrhage in internal organs has also been described after autopsy [8]. This has led to 
the hypothesis that skin damage in Fusarium infection involves the vessels, and that 
thrombosis explains the frequent necrotic feature. In our cases, early skin biopsies allowed 
us to find microvessel thrombosis, associated with hyphae, but we did not observe 
necrosis. In an animal study, necrotizing abscesses with acute branching septate hyphae, 
neutrophil and macrophage infiltration were found in nonneutropenic mice, whereas 
neutropenic mice did not have inflammation and had a higher fungal burden [8]. The 
absence of necrosis in our two patients could be linked to the fact that they were 
neutropenic, and/or to the fact that they were biopsied early, before necrosis followed 
microvessel thrombosis. 
Among the 8 cases of fusariosis with hyphae presence within skin vessels reported in 
the literature (table 1), only two cases showed thrombosis in large vessels (retinal vessel 
and superficial suppurative thrombophlebitis after antecubital intravenous catheter). 
However, 7 out of the 8 cases had skin necrosis, which suggests that microvessel 
thrombosis is a frequent event. In our cases, the fact that the skin biopsies were performed 
early in the course of the disease allowed us to recognize microvessel thrombosis with 
hyphae. Rapid start of the specific treatment might have prevented worsening of skin 
lesions and further necrosis.  
Early skin biopsy also allows the fungal culture from the skin specimen. The diagnosis 
of Fusarium infection was established on skin sample culture in our cases. The value of 
skin sample culture has been recently underlined, since the blood culture isolates the 
Fusarium in only approximately 70% of reported cases [2]. However, cultures require 
several days to enable a diagnosis whereas histology results can be obtained more rapidly. 
Specific stains show hyphae filaments (phialides) and unicellular form spores 
(phialoconidia) in a closed lesion [8]. However, discrimination between Fusarium species  
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and other non-Aspergillus hyalohyphomycoses species is difficult by histopathologic 
examination and culture remains the standard for identification of these fungi. 
Differential diagnosis with Aspergillus can be difficult. Both Aspergillus and Fusarium 
progress through vascular invasion with sometimes vascular wall rupture leading to 
severe tissue damage. Histopathology shows similar acute branching septate hyphae 
although hyphae branching of both 45 and 90 degrees are present and hyphae diameter 
is smaller and irregular in Fusarium in opposite to Aspergillus. Furthermore, 
immunostainings with specific monoclonal antibodies not performed in our cases have 
proved to be a powerful tool for the accurate diagnosis of systemic mycoses, including 
aspergillosis and fusariosis [9]. 
In the treatment of invasive fungal infections, systematic antifungal susceptibility 
testing is recommended [6]. Because of a lack of clinical trials and the critical role of 
immune reconstitution in the outcome of fusariosis, the optimal treatment strategy for 
patients with severe fusarial infection has to be defined. In a retrospective analysis of 
84 patients with haematologic diseases and invasive fusariosis, treatment was 
deoxycholate amphotericin or a lipid formulation of amphotericin B. 27 patients (32%) 
responded to treatment, but only 18 patients (21%) were still alive 90 days after diagnosis. 
The response rate to a lipid formulation of amphotericin B appeared to be superior to that 
to deoxycholate amphotericin B (46% vs. 32%, respectively), but the difference was not 
statistically significant (p < 0.36) [10]. In another study, voriconazole was given to 
11 patients with fusariosis, all intolerant or refractory to primary therapy. The response 
rate was 45%, with a 90-day actuarial survival of 71% [11]. Posaconazole has also been 
used as salvage therapy among 21 patients with proven or probable fusariosis. All but one 
patient were initially treated with a lipid-based formulation of amphotericin B. The 
overall success rate (complete plus partial response) was 48% [12]. Data on combination 
therapy for fusariosis are limited to a few case reports: caspofungin plus amphotericin B 
[13], amphotericin B plus voriconazole [14], amphotericin B and terbinafine [15]. Given 
the scarcity of data, no solid recommendations for combination therapy can be provided. 
The prevention and treatment of invasive fungal infections, aspergillosis and fusariosis, 
include standard and liposomal formulations of amphotericin B. Newer azoles, 
particularly voriconazole and posaconazole, have an enhanced spectrum of activity 
including Aspergillus and Fusarium species. Recently, therapeutic recommendations in 
invasive fusariosis suggest a high dose of amphotericin B for F. solani/F. verticolloides and 
a high dose of amphotericin B or voriconazole for other Fusarium species [6]. 
To conclude, in early cutaneous biopsies of immunocompromised patients, the 
presence of cutaneous vessel thrombosis can suggest a fungal infection and presence of 
hyphae confirms the fungal infection. Vessel thrombosis may help to start specific therapy 
without delay for these life-threatening infections. 
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Table 1. Reported cases of Fusarium infections with hyphae presence within skin vessels 
Case  Age  Sex  Species  Outcome  Initial disease  Type of infection  Skin  
necrosis 
Throm- 
bosis 
Refer-
ence 
01 20  F oxysporum died  ALL  +  BMT  disseminated  yes  no  07 
02 59  M  oxysporum died  ALL  +  BMT  disseminated  yes  no  08 
03 29  M  NA  unknown  ALL  disseminated  yes  no  09 
04 53  M  solani died  renal  graft  disseminated  yes  no  10 
05 51  M  NA  died  AIDS  disseminated  yes  yes  11 
06 35  F moniliforme died  ALL  skin  only  yes  no  12 
07  05 M moniliforme died  ALL  skin  only  yes  no  13 
08 79  F proliferatum resolved face  trauma  vein  no  yes  14 
09* 16 M subglutinans died  HUAL  skin  no  yes   
10* 50 F  solani resolved  renal  graft  skin  no  yes   
F = Female; M = male; NA = not available; ALL = acute lymphoid leukaemia; BMT = bone 
marrow transplantation; AIDS = acquired immunodeficiency syndrome; HUAL = hyperleukocytic 
undifferentiated acute leukaemia. * Present study. 
 
 
 
 
Fig. 1. a Case 1: Skin biopsy performed two days after the eruption onset. Left: purpuric blisters; 
middle: microvessel thrombosis in the papillary dermis, hematoxylin-eosin stain, ×400; right: following 
section at the same magnification; presence of multiple hyphae within the microvessel thrombus, 
Gomori-Grocott stain (scale bar = 300 μm). b Case 2: Skin biopsy performed three days after the 
eruption onset. Left: erythematous papules centered by pustules; middle: microvessel thrombosis in the 
hypodermis, hematoxylin-eosin stain, ×400; right: reticulin silver stain showing the basal lamina of the 
microvessel and hyphae within the thrombus, following section, ×400 (scale bar = 300 μm). 
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